β-Muricholic Acid
(Synonyms: Β-鼠胆酸,5β-Cholanic Acid-3α,6β,7β-triol, β-MCA) 目录号 : GC40719β-胆酸β-muricholic acid是一种天然存在的三羟基亲水性胆汁酸，作为胆道胆固醇去饱和剂，促进胆固醇胆结石的溶解。
Cas No.:2393-59-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
β-Muricholic acid is a naturally occurring trihydroxy hydrophilic bile acid, as a biliary cholesterol-desaturating agent and facilitates the dissolution of cholesterol gallstones. It found in mice and differs from human primary bile acids by featuring a hydroxyl group in the β- configuration at the 6-position[1-3].
β-muricholic acid(100 µM；48h) inhibited lipid accumulation in primary-cultured mouse hepatocytes after exposure to palmitic acid (PA)/oleic acid (OA), it may be useful in the treatment of nonalcohol fatty liver disease (NAFLD) [4].
β-muricholic acid(0.5% β-muricholic acid in food; p.o; 8 weeks) is more effective than UDCA in enhancing the dissolution rates of cholesterol gallstones via increasing a liquid crystals-containing phase. Addition of beta-muricholic acid decreased gallstone prevalence to 20% through significantly reducing biliary secretion rate, saturation index, and intestinal absorption of cholesterol that prevented the transition of cholesterol from its liquid crystalline phase to solid crystals and stones [5].
[1]. Denk GU, Kleiss CP, et,al. Tauro-β-muricholic acid restricts bile acid-induced hepatocellular apoptosis by preserving the mitochondrial membrane potential. Biochem Biophys Res Commun. 2012 Aug 10;424(4):758-64. doi: 10.1016/j.bbrc.2012.07.029. Epub 2012 Jul 15. PMID: 22809502.
[2]. Montet JC, Parquet M, et,al. beta-Muricholic acid; potentiometric and cholesterol-dissolving properties. Biochim Biophys Acta. 1987 Mar 13;918(1):1-10. doi: 10.1016/0005-2760(87)90002-6. PMID: 3828364.
[3]. Sacquet E, Parquet M, et,al. Metabolism of beta-muricholic acid in man. Steroids. 1985 May;45(5):411-26. doi: 10.1016/0039-128x(85)90006-6. PMID: 3834660.
[4]. Takada S, Matsubara T, et,al. Stress can attenuate hepatic lipid accumulation via elevation of hepatic β-muricholic acid levels in mice with nonalcoholic steatohepatitis. Lab Invest. 2021 Feb;101(2):193-203. doi: 10.1038/s41374-020-00509-x. Epub 2020 Dec 10. PMID: 33303970.
[5]. Wang DQ, Tazuma S. Effect of beta-muricholic acid on the prevention and dissolution of cholesterol gallstones in C57L/J mice. J Lipid Res. 2002 Nov;43(11):1960-8. doi: 10.1194/jlr.m200297-jlr200. PMID: 12401895.
β-胆酸β-muricholic acid是一种天然存在的三羟基亲水性胆汁酸，作为胆道胆固醇去饱和剂，促进胆固醇胆结石的溶解。它在小鼠中发现，不同于人类的原胆汁酸，它在6位的β-结构中具有羟基[1-3]。
β-muricholic acid(100 µM；48h)可抑制暴露于棕榈酸(PA)/油酸(OA)后的原代培养小鼠肝细胞的脂质积累, 可能对治疗非酒精性脂肪肝(NAFLD)有用[4]。
β-muricholic acid(0.5% β-muricholic acid in food; p.o; 8 weeks)通过增加含液晶相，比UDCA更有效地提高胆固醇胆结石的溶解速率, 添加β-muricholic acid可显著降低胆汁分泌率、饱和指数和肠道对胆固醇的吸收，从而阻止胆固醇从液晶状态转变为固体晶体和结石，从而使胆结石患病率降至20%[5]。
| Cell experiment [1]: | |
Cell lines | Primary hepatocytes |
Preparation Method | Hepatocytes were exposed to 100 µM β-muricholic acid after treatment with palmitic acid (PA)/oleic acid (OA). |
Reaction Conditions | 100 µM；48h |
Applications | β-muricholic acid inhibited lipid accumulation in primary-cultured mouse hepatocytes after exposure to palmitic acid (PA)/oleic acid (OA). |
| Animal experiment [2]: | |
Animal models | Male C57L/J mice |
Preparation Method | For gallstone dissolution study, mice that have formed cholesterol gallstones were fed chow (control) with or without 0.5% ursodeoxycholic acid (UDCA) or 0.5% β-muricholic acid for 8 weeks. |
Dosage form | 0.5% β-muricholic acid in food; p.o; 8 weeks |
Applications | β-muricholic acid is more effective than UDCA in enhancing the dissolution rates of cholesterol gallstones via increasing a liquid crystals-containing phase. |
References: | |
| Cas No. | 2393-59-1 | SDF | |
| 别名 | Β-鼠胆酸,5β-Cholanic Acid-3α,6β,7β-triol, β-MCA | ||
| 化学名 | (5β)-3α,6β,7β-trihydroxy-cholan-24-oic acid | ||
| Canonical SMILES | OC(CC[C@@H](C)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@@H](O)[C@@H](O)[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C)=O | ||
| 分子式 | C24H40O5 | 分子量 | 408.6 |
| 溶解度 | 20mg/ml in ethanol & DMSO, 30mg/ml in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4474 mL | 12.2369 mL | 24.4738 mL |
| 5 mM | 0.4895 mL | 2.4474 mL | 4.8948 mL |
| 10 mM | 0.2447 mL | 1.2237 mL | 2.4474 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet